androstenediol has been researched along with Prostatic Neoplasms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blair, IA; Huang, M; Mesaros, C; Penning, TM; Tamae, D; Wang, Q; Zang, T | 1 |
| Bell, D; Corey, E; Frincke, J; Garsd, A; Reading, C; Stickney, D; Trauger, R; White, S | 1 |
| Arai, S; Honma, S; Kobayashi, M; Miyashiro, Y; Shibata, Y; Suzuki, K; Tomaru, Y | 1 |
| Mohler, JL; Titus, MA; Wilson, EM | 1 |
| Sharifi, N | 1 |
| Lundqvist, J; Norlin, M | 1 |
| Campbell, MJ; Doherty, D; Maguire, O; Martin, P; McClean, S; Owen, A; Pollock, C; Smyth, T; Thompson, P | 1 |
| Broeder, CE | 1 |
| Egawa, M; Fujita, H; Honma, S; Keller, ET; Koh, E; Koshida, K; Maeda, Y; Mizokami, A; Namiki, M | 1 |
| Bai, C; Chen, F; Freedman, L; Gambone, C; Harada, S; Kasparcova, V; Knecht, K; Leu, C; Reszka, A; Rutledge, SJ; Scafonas, A; Schmidt, A; Vogel, R; Zhang, H | 1 |
| Lardy, H; Marwah, A; Marwah, P | 1 |
| Higashi, T; Koh, E; Kyutoku, M; Namiki, M; Shimada, K; Takayama, N | 1 |
| Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D | 1 |
| Chang, C; Lardy, H; Messing, E; Miyamoto, H; Yeh, S | 1 |
| Chang, C; Chang, HC; Huang, KE; Lardy, H; Marwah, P; Miyamoto, H; Yeh, S | 1 |
| El Etreby, MF; Mahrous, AT | 1 |
| Bélanger, A; Brochu, M; Cliche, J | 1 |
| Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F | 1 |
3 review(s) available for androstenediol and Prostatic Neoplasms
| Article | Year |
|---|---|
Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Abiraterone Acetate; Androstadienes; Androstenediol; Antineoplastic Agents; Dehydroepiandrosterone; Etiocholanolone; Humans; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Testosterone | 2011 |
Oral andro-related prohormone supplementation: do the potential risks outweigh the benefits?
Topics: Androstenediol; Androstenediols; Androstenedione; Dietary Supplements; Estrogens; Humans; Lipoproteins, HDL; Male; Muscle, Skeletal; Prostatic Neoplasms; Risk Factors; Sexual Behavior; Testosterone | 2003 |
C(19)-5-ene steroids in nature.
Topics: Androstenediol; Animals; Dehydroepiandrosterone; Female; Health Status; Humans; Immunity; Male; Prostatic Neoplasms; Steroids | 2005 |
15 other study(ies) available for androstenediol and Prostatic Neoplasms
| Article | Year |
|---|---|
Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.
Topics: Androgens; Androstenediol; Calibration; Chromatography, Liquid; Female; Humans; Limit of Detection; Linear Models; Male; Picolinic Acids; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2017 |
Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).
Topics: Androstanols; Androstenediol; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Receptors, Androgen | 2009 |
Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues.
Topics: Adrenal Glands; Androgens; Androstenediol; Androstenedione; Castration; Chromatography, Liquid; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Male; Prostate; Prostatic Neoplasms | 2011 |
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.
Topics: Androstenediol; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Enzyme Inhibitors; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Signal Transduction; Steroid 17-alpha-Hydroxylase | 2011 |
Effects of CYP7B1-related steroids on androgen receptor activation in different cell lines.
Topics: Androgens; Androstenediol; Cell Line, Tumor; Cytochrome P450 Family 7; Gene Expression; HEK293 Cells; Humans; Male; Organ Specificity; Prostatic Neoplasms; Receptors, Androgen; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Steroid Hydroxylases; Testosterone; Transfection | 2012 |
Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor.
Topics: Androstenediol; Caco-2 Cells; Calcitriol; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP4A; Gene Expression Regulation; Humans; Ligands; Male; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Receptors, Calcitriol; Testosterone; Transfection | 2012 |
The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
Topics: Androgen Antagonists; Androgens; Androstenediol; Cell Division; Cell Line, Tumor; Dihydrotestosterone; DNA Primers; Genes, Reporter; Humans; Male; Mutation; Polymerase Chain Reaction; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen; Transfection | 2004 |
Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
Topics: Adaptor Proteins, Signal Transducing; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Androstenediol; Androstenedione; Anilides; Animals; Breast Neoplasms; Carrier Proteins; Cell Division; Chlorocebus aethiops; COS Cells; Cyproterone Acetate; Dihydrotestosterone; Humans; Ligands; Macaca mulatta; Male; Mammary Tumor Virus, Mouse; Mice; Nerve Tissue Proteins; Nitriles; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, AMPA; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
Liquid chromatography-mass spectrometric assay of androstenediol in prostatic tissue: influence of androgen deprivation therapy on its level.
Topics: Androstenediol; Chromatography, Liquid; Humans; Male; Molecular Structure; Prostate; Prostatic Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Alkaline Phosphatase; Androstenediol; Antineoplastic Agents, Hormonal; Bone Neoplasms; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Testosterone | 1997 |
Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.
Topics: Androgens; Androstane-3,17-diol; Androstenediol; Anilides; Flutamide; Humans; Male; Mutation; Nitriles; Nuclear Receptor Coactivators; Oncogene Proteins; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Steroids; Testosterone; Tosyl Compounds; Trans-Activators; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1998 |
Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.
Topics: Androstenediol; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Transcriptional Activation; Tumor Cells, Cultured | 1999 |
Immunocytochemical technique for detection of prolactin (PRL) and growth hormone (GH) in hyperplastic and neoplastic lesions of dog prostate and mammary gland.
Topics: Androstenediol; Animals; Castration; Cyproterone; Dogs; Estradiol; Female; Growth Hormone; Immunoenzyme Techniques; Male; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Prolactin; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms | 1979 |
Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer.
Topics: Aged; Androgens; Androstane-3,17-diol; Androstenediol; Androsterone; Dehydroepiandrosterone; Dihydrotestosterone; Glucuronates; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Testosterone | 1986 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstenedione; Androsterone; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dehydroepiandrosterone; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Kinetics; Luteinizing Hormone; Male; Pregnenolone; Progesterone; Prolactin; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |